Dec 09, 2024 9:15am EST Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Nov 18, 2024 8:30am EST Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Nov 13, 2024 8:30am EST Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Nov 12, 2024 8:00am EST Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 05, 2024 8:30am EST Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Oct 09, 2024 9:00am EDT Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Sep 04, 2024 9:00am EDT Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 13, 2024 8:00am EDT Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 15, 2024 8:30am EDT Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Jul 03, 2024 9:00am EDT Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
